Today, Bremer Trust National Association Sold shares of Gilead Sciences Inc. (GILD)

Today, Bremer Trust National Association Sold shares of Gilead Sciences Inc. (GILD)

Bremer Trust National Association reduced its position in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 22.6% during the third quarter, Holdings Channel reports. The fund owned 39,228 shares of the biopharmaceutical company’s stock after selling 11,425 shares during the period. Gilead Sciences makes up about 0.8% of Bremer Trust National Association’s portfolio, making the stock its 27th largest position. Bremer Trust National Association’s holdings in Gilead Sciences were worth $3,104,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. F&V Capital Management LLC boosted its position in Gilead Sciences by 3.7% in the third quarter. F&V Capital Management LLC now owns 78,410 shares of the biopharmaceutical company’s stock worth $6,204,000 after buying an additional 2,775 shares during the last quarter. Monarch Capital Management Inc. boosted its position in Gilead Sciences by 102.1% in the third quarter. Monarch Capital Management Inc. now owns 24,065 shares of the biopharmaceutical company’s stock worth $1,904,000 after buying an additional 12,160 shares during the last quarter. Independent Portfolio Consultants Inc. boosted its position in Gilead Sciences by 2.4% in the third quarter. Independent Portfolio Consultants Inc. now owns 15,456 shares of the biopharmaceutical company’s stock worth $1,223,000 after buying an additional 368 shares during the last quarter. Stillwater Investment Management LLC boosted its position in Gilead Sciences by 6.9% in the third quarter. Stillwater Investment Management LLC now owns 37,331 shares of the biopharmaceutical company’s stock worth $2,954,000 after buying an additional 2,400 shares during the last quarter. Finally, Franklin Street Advisors Inc. NC boosted its position in Gilead Sciences by 1.3% in the third quarter. Franklin Street Advisors Inc. NC now owns 220,802 shares of the biopharmaceutical company’s stock worth $17,470,000 after buying an additional 2,756 shares during the last quarter. Hedge funds and other institutional investors own 76.65% of the company’s stock.

Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded up 0.19% during mid-day trading on Friday, hitting $75.44. 3,068,606 shares of the stock were exchanged. Gilead Sciences Inc. has a 52-week low of $71.39 and a 52-week high of $108.31. The stock has a 50-day moving average price of $74.56 and a 200 day moving average price of $80.20. The firm has a market cap of $99.39 billion, a price-to-earnings ratio of 6.98 and a beta of 1.25.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $2.75 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.87 by $0.12. Gilead Sciences had a return on equity of 100.57% and a net margin of 47.74%. The business earned $7.40 billion during the quarter, compared to analysts’ expectations of $7.47 billion. During the same period last year, the company earned $3.22 earnings per share. The firm’s revenue was down 9.6% compared to the same quarter last year. On average, equities research analysts expect that Gilead Sciences Inc. will post $11.47 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 29th. Investors of record on Thursday, December 15th will be paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 2.49%. The ex-dividend date is Tuesday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 17.44%.

A number of research firms have weighed in on GILD. Leerink Swann reiterated a “market perform” rating and issued a $89.00 target price on shares of Gilead Sciences in a research note on Tuesday, November 15th. Stifel Nicolaus initiated coverage on shares of Gilead Sciences in a research note on Monday, November 14th. They set a “buy” rating and a $100.00 price target on the stock. They noted that the move was a valuation call. Jefferies Group restated a “buy” rating on shares of Gilead Sciences in a research note on Tuesday, November 8th. Mizuho initiated coverage on shares of Gilead Sciences in a research note on Monday, November 7th. They set a “buy” rating and a $88.00 price target on the stock. Finally, Zacks Investment Research upgraded shares of Gilead Sciences from a “strong sell” rating to a “hold” rating in a research note on Monday, November 7th. Ten equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and two have assigned a strong buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and an average price target of $97.90.

In related news, Director John W. Madigan sold 105,000 shares of the company’s stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $74.86, for a total value of $7,860,300.00. Following the completion of the sale, the director now directly owns 121,761 shares of the company’s stock, valued at $9,115,028.46. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider John F. Milligan sold 70,000 shares of the company’s stock in a transaction dated Tuesday, September 6th. The stock was sold at an average price of $77.74, for a total transaction of $5,441,800.00. Following the completion of the sale, the insider now directly owns 1,128,963 shares of the company’s stock, valued at $87,765,583.62. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Related posts

Leave a Comment